Background: Illicit drug use is a growing issue in Europe and leading cause of acute cardiac events in patients admitted to intensive cardiac care units. Indeed, cardiovascular complications are one of the main causes of death due to illicit drug use. However, its prevalence in patients hospitalized in intensive cardiac care units is unknown. Objectives: This large multicenter prospective study will assess the prevalence of illicit drug use in consecutive patients hospitalized in intensive cardiac care units by urine drug assay. Eligibility: * Patient over 18 years old admitted to intensive Cardiac Care Unit (CCU) for any reason. * Without hospitalization for a planned interventional procedure. * Without hospitalization for more than 24 hours at any hospital facility before admission to the CCU. Design: * Multicentre cohort study with a prospective enrolment of all consecutive patients admitted to the CCU to assess the prevalence of illicit drug use in 40 centers throughout France. * Participants will be screened with a physical exam, medical history and addiction survey. * Participants will be screened for drug use by urine drug assay (NarcoCheck®, Kappa City Biotech SAS, Montluçon, France) and for tobacco by standardized exhaled carbon monoxide (CO) measurement with a CO-Check Pro device (Bedfont Scientific Ltd, Kent, UK). * Participants will be followed at 6 months of follow-up to assess the occurrence of cardiovascular events.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Prevalence of psychoactive drug use assessed by urine drug assay at the time of patient admission.
Timeframe: Day 0